Next-Generation Nanobody Therapeutics Targeting KLRK1/KLRC4-KLRK1 for Autoimmune Disease Intervention
VHH-P355 is a fully humanized single-domain antibody (nanobody) specifically targeting killer cell lectin like receptor K1 (KLRK1) and KLRC4-KLRK1 readthrough (KLRC4-KLRK1). Developed using advanced expression in Escherichia coli strain SS320, VHH-P355 is positioned in the Biological Testing stage. The nanobody is engineered to modulate immune responses by binding to these immune checkpoint molecules, offering potential as a breakthrough therapy for autoimmune diseases. With its distinct molecular recognition and high specificity for KLRK1 and KLRC4-KLRK1, VHH-P355 represents a promising avenue for addressing unmet clinical needs in immune-mediated pathologies.
| Candidate | VHH-P355 |
| Target | killer cell lectin like receptor K1 (KLRK1) KLRC4-KLRK1 readthrough (KLRC4-KLRK1) |
| Modality | humanized bispecific VHH |
| Indication | Autoimmune Disease |
Licensing Opportunity
VHH-P355 is currently available for out-licensing opportunities. We welcome strategic collaborations with partners interested in advancing innovative nanobody therapeutics for autoimmune diseases through co-development or licensing arrangements.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P355 |
Modality
VHH-P355 leverages the structural and functional advantages of single-domain nanobody technology, being composed of a single variable domain targeting KLRK1 expressed in human immune cells. Its small molecular size ensures superior tissue penetration and rapid systemic distribution, critical for addressing inflammation in autoimmune diseases. Additionally, its robust physicochemical stability and high solubility, conferred by its unique structure and production in Escherichia coli SS320, enhance its manufacturability and suitability for chronic or complex indications. The modular format of VHH-P355 also enables flexible engineering into multivalent or multifunctional therapeutics tailored for diverse autoimmune contexts.
Target
KLRK1 and KLRC4-KLRK1 are type II transmembrane proteins predominantly expressed on natural killer (NK) cells, CD8+ T cells, and certain subsets of γδ T cells. Functioning as activating receptors, KLRK1 and KLRC4-KLRK1 play pivotal roles in immune surveillance and cytotoxic lymphocyte responses. Dysregulation of KLRK1/KLRC4-KLRK1 has been associated with aberrant activation of immune effector cells, contributing to the pathogenesis of autoimmune diseases. Targeting KLRK1/KLRC4-KLRK1 therefore presents a scientifically validated strategy for modulating overactive immune responses. VHH-P355’s high selectivity for KLRK1/KLRC4-KLRK1 positions it as a significant asset for developing targeted interventions, enabling potential disease modification and immune homeostasis in complex autoimmune conditions.
Mechanism of Action
VHH-P355 acts as a signal transduction modulator by specifically binding to the extracellular domain of KLRK1 and KLRC4-KLRK1, key type II integral membrane proteins also known as NKG2D family receptors. Through this interaction, VHH-P355 is designed to inhibit or fine-tune the downstream signaling pathways responsible for immune cell activation and cytotoxicity. This targeted approach aims to reduce inappropriate immune responses characteristic of autoimmune diseases without broadly suppressing essential immunity. Furthermore, the nanobody scaffold of VHH-P355 enables potential expansion into antibody-drug conjugates (ADCs), bispecifics, or multispecific formats, opening avenues for tailored immune modulation and combination therapies in evolving autoimmune disease landscapes.
Autoimmune Disease
Autoimmune diseases represent a diverse group of conditions characterized by the immune system’s aberrant attack on self-tissues, resulting in chronic inflammation and progressive organ dysfunction. These disorders encompass systemic and organ-specific entities, collectively affecting millions of individuals worldwide and imposing significant healthcare burdens. Current therapeutic approaches include immunosuppressive agents, biologics targeting specific cytokines or immune cells, and, in severe cases, cell-based therapies. However, many patients experience inadequate responses, relapse, or adverse effects due to non-selective immunosuppression, underlining the critical need for safer, more targeted interventions. VHH-P355, by precisely modulating the KLRK1/KLRC4-KLRK1 pathway, holds promise as a next-generation immune therapeutic, potentially enabling effective disease control while minimizing off-target immune suppression and paving the way for durable remission in challenging autoimmune indications.